Keith D.  Dawkins net worth and biography

Keith Dawkins Biography and Net Worth

Dr. Dawkins joined Shockwave in May 2019 as Chief Medical Officer. Prior to Shockwave, he served as Global Chief Medical Officer and Executive Vice President to Boston Scientific Corporation, as well as a member of the Executive Committee from 2012 to 2017. This role followed his time as Chief Medical Officer to the Boston Scientific Cardiology, Rhythm and Vascular Group from 2010 to 2012. He joined Boston Scientific in 2008 as Senior Vice President and Associate Chief Medical Officer of the cardiovascular business.

 

Earlier in his career, Dr. Dawkins was a practicing interventional cardiologist for more than 20 years in the U.K. He has earned a series of clinical, research and academic distinctions, including a Post-Doctoral Research Fellowship at Stanford University as a Fulbright Scholar. He served as President of the British Cardiovascular Intervention Society (BCIS) and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence (NICE). He has been an author on more than 750 academic publications and presentations on a variety of cardiac topics.

 

Dr. Dawkins earned a First Class Honours degree in Pathology at London University and Guy’s Hospital. He trained in cardiology at Oxford and at the Royal Brompton & St. George’s Hospital in London.

What is Keith D. Dawkins' net worth?

The estimated net worth of Keith D. Dawkins is at least $5.11 million as of February 7th, 2017. Dr. Dawkins owns 75,864 shares of Boston Scientific stock worth more than $5,114,751 as of April 18th. This net worth evaluation does not reflect any other assets that Dr. Dawkins may own. Learn More about Keith D. Dawkins' net worth.

How do I contact Keith D. Dawkins?

The corporate mailing address for Dr. Dawkins and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at [email protected]. Learn More on Keith D. Dawkins' contact information.

Has Keith D. Dawkins been buying or selling shares of Boston Scientific?

Keith D. Dawkins has not been actively trading shares of Boston Scientific during the last ninety days. Most recently, Keith D. Dawkins sold 80,783 shares of the business's stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $25.21, for a transaction totalling $2,036,539.43. Following the completion of the sale, the executive vice president now directly owns 75,864 shares of the company's stock, valued at $1,912,531.44. Learn More on Keith D. Dawkins' trading history.

Who are Boston Scientific's active insiders?

Are insiders buying or selling shares of Boston Scientific?

During the last twelve months, insiders at the medical equipment provider sold shares 25 times. They sold a total of 714,289 shares worth more than $38,671,106.81. The most recent insider tranaction occured on April, 1st when EVP John Bradley Sorenson sold 16,351 shares worth more than $1,133,124.30. Insiders at Boston Scientific own 0.5% of the company. Learn More about insider trades at Boston Scientific.

Information on this page was last updated on 4/1/2024.

Keith D. Dawkins Insider Trading History at Boston Scientific

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2017Sell80,783$25.21$2,036,539.4375,864View SEC Filing Icon  
5/10/2016Sell80,000$22.15$1,772,000.00150,227View SEC Filing Icon  
See Full Table

Keith D. Dawkins Buying and Selling Activity at Boston Scientific

This chart shows Keith D Dawkins's buying and selling at Boston Scientific by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Boston Scientific Company Overview

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $67.42
Low: $67.22
High: $68.20

50 Day Range

MA: $67.21
Low: $64.97
High: $68.84

2 Week Range

Now: $67.42
Low: $48.35
High: $69.21

Volume

5,946,636 shs

Average Volume

6,369,347 shs

Market Capitalization

$98.91 billion

P/E Ratio

63.01

Dividend Yield

N/A

Beta

0.78